Moderna Says It Is Prepared To Submit For Approval A Covid Vaccine Targeting Either JN.1 Or KP.2 Variant
Portfolio Pulse from Benzinga Newsdesk
Moderna announced its readiness to submit for approval a COVID-19 vaccine targeting either the JN.1 or KP.2 variant.
June 05, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna is prepared to submit for approval a COVID-19 vaccine targeting either the JN.1 or KP.2 variant. This development could potentially boost Moderna's stock as it shows the company's ongoing efforts to address emerging COVID-19 variants.
The announcement indicates that Moderna is actively working on vaccines for new COVID-19 variants, which could lead to increased demand and revenue. This is likely to have a positive short-term impact on Moderna's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100